Single versus multiple inhaler triple therapy in COPD using data from the pragmatic INTREPID trial: cost-effectiveness analysis from the Chilean public healthcare system perspective
Expert Review of Pharmacoeconomics & Outcomes Research · 09.08.2026 · 26 (7) · 903-911
DOI: 10.1080/14737167.2026.2693168 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 29.06.2026. Verfasst von Felipe Moraes Dos Santos und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical Department, GSK, Santiago, Chile. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Quinuclidines, Bronchodilator Agents, Chlorobenzenes. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: GlaxoSmithKline.
Themen: COPD
Abstract (Originalsprache)
BACKGROUND: Chronic obstructive pulmonary disease (COPD) imposes a substantial economic burden in Chile. This study assessed the cost-effectiveness of fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) once daily via single inhaler compared to multiple inhaler triple therapy (MITT) for moderate to severe COPD, from the Chilean public healthcare system perspective. RESEARCH DESIGN AND METHODS: The Galaxy COPD disease progression model was adapted to the Chilean setting, incorporating Chilean healthcare resource use and unit costs, along with patient data, comparators, and treatment effects from INTREPID trial. Costs and healthcare benefits were aggregated over 25 years and reported as incremental cost-effectiveness ratios (ICERs-cost/quality-adjusted life year [QALY] gained). Sensitivity analysis included probabilistic assessment. RESULTS: Single inhaler FF/UMEC/VI provided an additional 0.261 QALYs at an incremental cost of 114.21 United States Dollars (USD) per patient, leading to an ICER of 438.41 USD/QALY in the base case. FF/UMEC/VI reduced severe exacerbations per patient per year by 4.38% compared to MITT. FF/UMEC/VI was dominant over MITT in 5- and 10-year time horizons. CONCLUSIONS: Despite higher total costs due to increased drug acquisition, FF/UMEC/VI reduces healthcare resource utilization associated with COPD events, representing a cost-effective option compared to MITT for moderate to severe COPD in Chile. Patients with chronic obstructive pulmonary disease (COPD) must deal with several symptoms that include dyspnea, cough, and sputum production. In Chile, about 40% of the patients experience episodes of disease exacerbation per year, while at least one of these leads to a hospitalization. Individuals with higher risk of exacerbations demand the use of several treatments that can be used on single or multiple inhalers. The single-inhaler therapy may be more convenient and effective than multiple inhalers in terms of treatment adherence. However, nowadays there are several therapeutic options in the market and limited financial resources. The present analysis assessed the balance between costs and clinical benefits of the treatment with a single inhaler versus multiple inhalers among patients with moderate to severe COPD. Considering the Chilean healthcare system perspective, treatment with single-inhaler promotes greater clinical benefits, while the cost is under a predefined willingness-to-pay threshold, when compared to multiple inhalers. Thus, it represents an important option for enhancing COPD management in Chile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Department, GSK, Santiago, Chile.
- School of Public Health, Pontificia Universidad Católica de Chile, Santiago, Chile.
- Epsilon Research, Santiago, Chile.
- Global Value Evidence and Outcomes, GSK, Mississauga, Ontario, Canada.
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
Förderung
- GlaxoSmithKline
Zitieren
APA
Dos Santos, F. M., Sandoval Astudillo, N., Espinoza, M., Balmaceda, C., Fernando Romero, J., & Noorduyn, S. G. (2026). Single versus multiple inhaler triple therapy in COPD using data from the pragmatic INTREPID trial: cost-effectiveness analysis from the Chilean public healthcare system perspective. Expert Review of Pharmacoeconomics & Outcomes Research, 26(7), 903-911. https://doi.org/10.1080/14737167.2026.2693168
Vancouver
Dos Santos FM, Sandoval Astudillo N, Espinoza M, Balmaceda C, Fernando Romero J, Noorduyn SG. Single versus multiple inhaler triple therapy in COPD using data from the pragmatic INTREPID trial: cost-effectiveness analysis from the Chilean public healthcare system perspective. Expert Review of Pharmacoeconomics & Outcomes Research. 2026;26(7):903-911. doi:10.1080/14737167.2026.2693168
BibTeX
@article{DosSantos2026,
author = {Dos Santos, Felipe Moraes and Sandoval Astudillo, Nicolás and Espinoza, Manuel and Balmaceda, Carlos and Fernando Romero, Jose and Noorduyn, Stephen G},
title = {Single versus multiple inhaler triple therapy in COPD using data from the pragmatic INTREPID trial: cost-effectiveness analysis from the Chilean public healthcare system perspective},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2026},
volume = {26},
number = {7},
pages = {903--911},
doi = {10.1080/14737167.2026.2693168}
}
EUVIMED